Analysts Bullish on Alnylam Pharmaceuticals Ahead of Upcoming Investor Conferences

Biotechnology Firm's Stock Price Target Raised by RBC Capital

Leading Analysts Reiterate Buy Ratings

Alnylam Pharmaceuticals (ALNY), a pharmaceutical company specializing in RNA interference, has garnered positive attention from analysts ahead of its upcoming investor conferences in November. On Friday, RBC Capital Markets raised its price target for ALNY from $265.00 to $300.00 while maintaining an Outperform rating.

Joseph Stringer, an analyst at Needham, also reaffirmed his Buy rating for ALNY. In a research note, Stringer highlighted the company's promising pipeline and potential for growth in the RNA interference market.

Citi analyst David Lebovitz has maintained his bullish stance on ALNY stock, assigning a Buy rating. Lebovitz cited the company's strong financial performance and its leadership in the development of RNA interference therapies.

Alnylam Pharmaceuticals is scheduled to participate in two major investor conferences in November. On November 9th, the company will present at the Stifel Healthcare Conference in New York City. On November 16th, ALNY will participate in the Barclays Global Healthcare Conference in Miami.

Investors eagerly anticipate these conferences for insights into the company's latest developments and its prospects for the future. Analysts' positive ratings and raised price targets signal continued confidence in Alnylam Pharmaceuticals' growth trajectory.